TwitterFacebookLinkedIn

December 8, 2018: Precision Vaccinations – Phase 2 cancer study evaluating T cell-activating immunotherapy MEDI0457 with MedImmune’s durvalumab targeting several HPV-related cancers.

Inovio Pharmaceuticals announced the first patient dosing in a Phase 2 combination study targeting a broad array of cancers associated with the human papillomavirus (HPV), which is a group of more than 200 related viruses.

This open-label study is sponsored by Dr. Michael Frumovitz, MD, MPH, of the MD Anderson Cancer Center in Houston, Texas,  where the trial will be conducted as part of MD Anderson’s “Moon Shot” cancer initiative.

Read more.